Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe complication of transplant. TA-TMA is a multifactorial disease where generalized endothelial dysfunction leads to microangiopathic hemolytic anemia, intravascular platelet activation, and formation of microthrombi leading to end-organ injury. It is essential to identify patients at risk for this complication and to implement early interventions to improve TA-TMA associated transplant outcomes.

          Related collections

          Author and article information

          Journal
          Expert Rev Hematol
          Expert review of hematology
          Informa UK Limited
          1747-4094
          1747-4094
          August 2021
          : 14
          : 8
          Affiliations
          [1 ] Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
          [2 ] Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
          Article
          10.1080/17474086.2021.1960816
          34301169
          0f9c5dd4-4737-4c80-9398-8cd16a21cc10
          History

          eculizumab,vasculopathy,stem cell transplant,endothelial injury,complement,Thrombotic microangiopathy

          Comments

          Comment on this article